Erschienen in:
01.03.2020 | Correspondence
Loss of H3K27 trimethylation by immunohistochemistry is frequent in oligodendroglioma, IDH-mutant and 1p/19q-codeleted, but is neither a sensitive nor a specific marker
verfasst von:
Melike Pekmezci, Joanna J. Phillips, Fikret Dirilenoglu, Turkan Atasever-Rezanko, Tarik Tihan, David Solomon, Andrew Bollen, Arie Perry
Erschienen in:
Acta Neuropathologica
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
The integrated diagnosis for infiltrating gliomas requires demonstration of
IDH1 or
IDH2 mutation and 1p/19q codeletion in the tumor to diagnose
oligodendroglioma or
anaplastic oligodendroglioma, IDH-
mutant and 1p/19q-
codeleted. IDH1 R132H, ATRX and p53 immunohistochemistry may help triaging cases for 1p/19q testing [
3]. Recently, Filipski et al. [
2] have reported that loss of H3K27me3 (trimethylation of lysine 27 of histone 3) stain could potentially stratify IDH-mutant diffuse gliomas based on cell type, recommending H3K27me3 stain as an additional marker in the immunohistochemical workup. A separate study reported differential loss of H3K27me3 staining in oligodendrogliomas and astrocytomas, which was only true using the monoclonal antibody [
1]. We have therefore assembled a validation cohort of genetically well-characterized adult diffuse gliomas to assess the clinical utility of H3K27me3 immunohistochemistry in this setting. …
